A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT04556773. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer
Study identification
- NCT ID
- NCT04556773
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Interventions
- Trastuzumab deruxtecan Drug
- Durvalumab Drug
- Paclitaxel Drug
- Capivasertib Drug
- Anastrozole Drug
- Fulvestrant Drug
- Capecitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 16, 2020
- Primary completion
- Aug 15, 2023
- Completion
- May 31, 2027
- Last update posted
- Aug 2, 2026
2020 – 2027
United States locations
- U.S. sites
- 9
- U.S. states
- 4
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Commack | New York | 11725 | — |
| Research Site | Harrison | New York | 10604 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Uniondale | New York | 11553 | — |
| Research Site | Chapel Hill | North Carolina | 27514 | — |
| Research Site | Chattanooga | Tennessee | 37404 | — |
| Research Site | Germantown | Tennessee | 38138 | — |
| Research Site | Fort Worth | Texas | 76104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04556773, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04556773 live on ClinicalTrials.gov.